Archives de la catégorie : Events

Washington DC – PresentationAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide a clinical update on OVX836 as part of a presentation entitled “Clinical Development Update on OVX836 disruptive T-cell vaccine for broad-protection against multiple influenza strains”. 

Virtual – PresentationAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide a clinical update on OVX836 as part of a presentation entitled “OVX836, a next generation universal Influenza vaccine focusing on T-Cell responses: Update on the clinical development plan”. 

Virtual – PosterAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to present additional efficacy endpoints of OVX836 as part of a poster entitled « OVX836, NP-based universal influenza vaccine candidate: results of phase 2a clinical trial ». 

Virtual – Oral PresentationAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide a clinical update on OVX836 as part of a presentation entitled « A new approach towards a universal influenza vaccine: clinical update of OVX836 ». 

Lyon – Oral PresentationDelphine Guyon-Gellin, Chief of Business Development of Osivax, to provide a clinical update on OVX836 as part of a presentation entitled « A new approach towards a universal influenza vaccine: clinical update of OVX836 ». 

Virtual – Oral PresentationAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide the last clinical results of OVX836 as part of a presentation entitled « OVX836, NP-based universal influenza vaccine candidate: results of phase 2a clinical trial ». 

Virtual – PosterAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to present the last clinical results of OVX836 as part of a poster entitled « OVX836, NP-based universal influenza vaccine candidate: results of phase 2a clinical trial ». 

Lyon – Oral PresentationAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide a general update on OVX836 as part of a presentation entitled « the development of a universal influenza vaccine: a precision approach to control diversity – NP as an attractive target for T cell based universal flu vaccine. »

Virtual – Oral PresentationAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide the last clinical results of OVX836 as part of a presentation entitled « OVX836, NP-based universal influenza vaccine candidate: results of phase 2a clinical trial ». 

Virtual – Oral PresentationAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide the last clinical results of OVX836 as part of a presentation entitled « OVX836, NP-based universal influenza vaccine candidate: results of phase 2a clinical trial ».